Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eprodisate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | GMNN | O75496 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | HBB | P68871 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | BBOX1 | O75936 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eprodisate SCHEMBL11909837 | 0.92 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2GMNNLMNATP53 | |
| Eprodisate SCHEMBL2288868 | 0.92 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2GMNNLMNATP53 | |
| Eprodisate SCHEMBL4422542 | 0.92 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2GMNNLMNATP53 | |
| Eprodisate SCHEMBL2519328 | 0.92 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2GMNNLMNATP53 | |
| Eprodisate SCHEMBL293813 | 0.92 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2GMNNLMNATP53 | |
| Eprodisate SCHEMBL218553 | 0.92 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2GMNNLMNATP53 | |
| Eprodisate SCHEMBL2522165 | 0.92 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2GMNNLMNATP53 | |
| Eprodisate SCHEMBL12979823 | 0.92 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2GMNNLMNATP53 | |
| SCHEMBL14974551 | 0.85 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2GMNNLMNATP53 | |
| Lithium Ion SCHEMBL28490449 | 0.85 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2GMNNLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266814-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR DELIVERING 1,3-PROPANEDISULFONIC ACID | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2015-09-24 | — | — | US | disclosed |
| US-9051248-B2 | Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid | BHI LIMITED PARTNERSHIP (CA) | 2015-06-09 | — | — | US | disclosed |
| US-20120208850-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR DELIVERING 1,3-PROPANEDISULFONIC ACID | BELLUS HEALTH INC. (CA) | 2012-08-16 | — | — | US | disclosed |
| EP-2464626-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR DELIVERING 1,3-PROPAN ED ISULFONIC ACID | Bellus Health Inc. (CA) | 2012-06-20 | — | — | EP | disclosed |
| US-8088548-B2 | Bottom antireflective coating compositions | AZ ELECTRONIC MATERIALS USA CORP. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2011017800-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR DELIVERING 1,3-PROPAN ED ISULFONIC ACID | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2011-02-17 | — | — | WO | disclosed |
| US-20090104559-A1 | Bottom Antireflective Coating Compositions | MERCK PATENT GMBH (DE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090104559-A1 | Bottom Antireflective Coating Compositions | SDC2, S100A9, MYH9 | ALDH1A1 3154/4885SMN1; SMN2 579/4885GMNN 571/4885 |
| US-20120208850-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR DELIVERING 1,3-PROPANEDISULFONIC ACID | SGMS1, GSS, HPGDS | ALDH1A1 174/4885SMN1; SMN2 61/4885GMNN 487/4885 |
| US-20150266814-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR DELIVERING 1,3-PROPANEDISULFONIC ACID | SGMS1, GSS, HPGDS | ALDH1A1 174/4885SMN1; SMN2 61/4885GMNN 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.